Implementation of a proprietary platform for preclinical in vitro drug testing
Project Information
Living Networks is a highly investment-ready startup offering a validated, patent-pending technology for preclinical and clinical drug testing using in vitro vascularized human microtissues (3D cultures). As the only company in Poland providing such functional tests, its platform includes access to specialized biological laboratories, research equipment, a qualified team, and dedicated image analysis software. The presence of blood vessels in these microtissues is critical for evaluating drug efficacy, especially for anticancer therapies and immunotherapies targeting the tumor microenvironment, and for assessing compound toxicity on microcirculation. The company has already established advanced traction, engaging in discussions and planning joint projects with major pharmaceutical corporations, mid-sized biotech firms, cosmetic companies, and startups.
Project tasks:
Collaborating with a renowned patent attorney specializing in biotechnology to manage and advance international intellectual property (IP) protection.
Preparing and filing the necessary documentation to enter the national phases of the international PCT patent application (PCT/PL2024/050024) in key global markets, including Europe, the United States, China, Japan, Canada, and South Korea.
Executing targeted promotional and business development activities to acquire initial clients for pilot programs.
Adapting the 3D testing platform to meet the specific requirements of early clients, which includes the potential streamlining and optimization of internal technological processes.
Target group:
Large pharmaceutical corporations.
Mid-sized biotechnology companies focused on drug discovery and biological compounds.
Biotech startups developing new drug candidates.
Cosmetic companies seeking advanced preclinical testing for specialized dermatological products, such as those addressing vascular skin conditions.
Companies specializing in the modeling of cellular therapies.
Project goals:
To achieve full investment readiness for Venture Capital funding within the 4-month acceleration period.
To strategically secure and protect the company's core intellectual property (the technology for generating 3D vascularized tissue models and dedicated software) across highly developed international markets where alternative preclinical models are rapidly advancing.
To validate the company's business assumptions and commercial viability through direct collaboration and testing with early adopters in the pharmaceutical and biotech sectors.
Effects and outcomes:
Successful initiation of the national phases for the PCT patent application, including the submission of all required applications and payment of official fees in target international patent offices.
Long-term legal security and protection of the company's key technology on a global scale.
The successful acquisition of corporate partners to conduct pilot testing programs.
Securing the company's first paying client, serving as definitive proof of market demand and commercial readiness.
Project Value and Funding Amount
Total amount of funding
129 743,68 PLN
Total cost of the project
139 458,28 PLN
#FunduszeUE#FunduszeEuropejskie
Project partners
Living Networks Sp. z o.o.
ul. Kasprzaka 44/52, 01-224 Warsaw, Poland